Company Information
Message

Our mission is to contribute to society through support to produce
safe and reliable biopharmaceuticals and new modalities
utilizing cutting-edge know-how and analytical technology.

U-Medico Inc.
CEO
Ayano Fukuhara, Ph.D.

U-Medico Inc., a spin-out from Osaka University, is an analytical and research service provider of biopharmaceuticals and new modalities. We provide high-quality analytical and formulation development services for biopharmaceuticals, including antibodies and fusion proteins, as well as gene therapeutics, to more than 40 domestic and international clients annually. We provide comprehensive support to our clients from the drug discovery stage through drug development, submission, and post-approval, contributing to safe and reliable drug development.

Our strength is our world-leading analytical technology, extensive experience, and unique know-how in utilizing that technology. In particular, we have a strong background in unique and highly accurate biophysical characterization, including analytical ultracentrifugation (AUC), hydrogen/deuterium exchange mass spectrometry (HDX-MS), and particles and aggregates analysis. We have helped our clients solve problems in pharmaceutical development.

In formulation development services, we entered into a strategic partnership with Coriolis Pharma, a world-leading company in formulation research and development, to further improve our technologies. Technical collaboration is being promoted to realize innovative formulation development services.

Furthermore, in April 2022, U-Medico launched its Cell and Gene Therapy Unit to take responsibility for the future of pharmaceuticals. In recent years, gene therapy, in which therapeutic genes are introduced into the body to treat genetic diseases fundamentally, has been gaining attention. The unit will provide intensively world-class analytical and quality testing services to ensure the stable production of high-quality cell and gene therapies.

We listen sincerely to our clients' concerns and propose solutions and new opportunities. As an analytical expert, researcher, and consultant, we will accompany you on your drug development journey. We hope you will use our knowledge and experience in your business.

U-Medico Inc.
CSO
Susumu Uchiyama, Ph.D.

Partnership

Laboratory of Macromolecular Biotechnology (Uchiyama Laboratory)
Department of biotechnology, Graduate School of Engineering Osaka University

Many foods and pharmaceuticals are made using biotechnology. In Uchiyama Laboratory, the goal is to understand the physical properties, structures, and functions of solutions and gels of proteins, nucleic acids, polysaccharides, and other biological "macromolecules" that constitute foods, gene therapy vectors, and biopharmaceuticals, and to contribute to the production of high-quality and safe foods and pharmaceuticals.

Find out more under www.macromolecularbiotechnology.com

Through our collaboration with Osaka University, we conduct research on physical properties for the development of high-quality biopharmaceuticals. We also develop technologies for analysis and quality control of therapeutic viral vectors.

Coriolis Pharma

Coriolis Pharma is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs including proteins, peptides, monoclonal antibodies, nucleic acids, virus-like particles, vaccines, advance therapy medicinal products (ATMPs) and genetically modified organisms (GMOs). Coriolis Pharma offers integrated development services for liquid and lyophilized formulations with all required technologies and analytical methods available in house. For each individual project, highly skilled scientists develop tailor-made study designs that align with the clients’ drug development strategy. With science-driven innovative solutions, Coriolis Pharma supports all phases of drug development including troubleshooting, batch-release testing including innovative methods and formulation optimization even beyond market approval. Coriolis’s mission is: formulating innovation!

Find out more under www.coriolis-pharma.com

CThrough our collaboration with Coriolis Pharma, we aim to provide innovative formulation development services for biopharmaceuticals and new modalities.

Company profile

Company Name U-Medico Inc.
Address 502 Photonics Center, Osaka University
2-1 Yamadaoka, Suita,
Osaka, 565-0871 Japan
TEL +81-6-6155-7835
Email info@u-medico.co.jp
Representative CEO Ayano Fukuhara, Ph.D.
Establishment August 2006
Access

502 Photonics Center, Osaka University
2-1 Yamadaoka, Suita,
Osaka, 565-0871 Japan

Photonics Center, Osaka University